Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 685 participants.
Also called NCT05099770
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 685 participants
- Sponsor
- Prokidney
- Registry
-
NCT05099770
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Mexico, Puerto Rico, Taiwan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05099770. Randomized; triple masking; primary purpose treatment. Start 2022-01-05 (actual); primary completion 2029-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Chronic Kidney Diseases
- Intervention (Biological)
- Renal Autologous Cell Therapy (REACT/ rilparencel)
- Intervention (Procedure)
- Sham Comparator
- Lead sponsor
- Prokidney
Record details
- Record id
cardio:ct-nct05099770- Content hash
c9d69f667e90446ba1a11c0119270fc6b3dce0f2e3602fad79fc9d4b5a0911e9